AU Patent

AU2018270112A1 — Combination therapies for treating cancer

Assigned to Tesaro Inc · Expires 2019-12-12 · 6y expired

What this patent protects

The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.

USPTO Abstract

The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.

Drugs covered by this patent

Patent Metadata

Patent number: AU2018270112A1
Jurisdiction: AU
Classification: —
Expires: 2019-12-12
Drug substance claim: No
Drug product claim: No
Assignee: Tesaro Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.